Intuitive Surgical (ISRG)
(Delayed Data from NSDQ)
$507.42 USD
+1.08 (0.21%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $507.62 +0.20 (0.04%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$507.42 USD
+1.08 (0.21%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $507.62 +0.20 (0.04%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth B Momentum C VGM
Zacks News
Orthofix (OFIX) Stock Declines 13% on '18 Earnings View Cut
by Zacks Equity Research
Despite the bottom line of Orthofix (OFIX) betters estimates, the company's shares drop due to trimmed 2018 earnings outlook.
Trade Tensions Begin to Escalate: Global Week Ahead
by John Blank
Markets will be gradually informed by developments in U.S.-China trade tensions over the coming weeks.
Chemed (CHE) Stock is Worth a Bet Right Now: Here's Why
by Zacks Equity Research
Chemed (CHE) sees a stellar Q1 backed by steady year-over-year revenue growth in both of its subsidiaries.
Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year?
BioScrip (BIOS) Q1 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
BioScrip's (BIOS) shift in strategy to raise core revenue mix hampers growth in Q1. Year-over-year rise in core product mix buoys optimism.
Anatomy of Success: Intuitive Surgical (ISRG)
by Ryan McQueeney
If investors had followed our model when it identified this futuristic healthcare technology manufacturer, they would have achieved massive profits.
Here's Why You Should Invest in Intuitive Surgical Right Now
by Zacks Equity Research
Intuitive Surgical (ISRG) gains on solid Q1 results and strength in da Vinci platform.
STERIS (STE) Q4 Earnings & Revenues Beat Estimates, Up Y/Y
by Zacks Equity Research
Favorable underlying market trends along with a slew of new product and service offerings by STERIS (STE) instill confidence in investors.
Wright Medical (WMGI) Beats on Q1 Earnings, Keeps Guidance
by Zacks Equity Research
Wright Medical's (WMGI) Q1 results solid; growth in upper and lower extremities segments encourages.
Haemonetics (HAE) Q4 Earnings Meet, Revenues Beat Estimates
by Zacks Equity Research
Continued generation of new business and geographical expansion drive Haemonetics' (HAE) Q4 results.
Penumbra (PEN) Q1 Earnings & Revenues Top Estimates, View Up
by Zacks Equity Research
Penumbra (PEN) benefits from strong growth across all geographies and product lines in Q1.
Luminex (LMNX) Beats Q1 Estimates on ARIES Platform Strength
by Zacks Equity Research
Luminex (LMNX) gains on ARIES and VERIGENE platforms in Q1; a solid guidance encourages.
Fresenius Medical (FMS) Misses on Q1 Earnings, Lowers View
by Zacks Equity Research
Lackluster performance in North America and foreign exchange headwinds mar Fresenius Medical's (FMS) bottom line in Q1.
Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q3
by Zacks Equity Research
Myriad Genetics' (MYGN) Q3 revenues decline year over year. Strong demand for GeneSight, Vectra DA and Prolaris tests was encouraging.
Henry Schein's (HSIC) Q1 Earnings Beat, '18 View Intact
by Zacks Equity Research
We currently await the completion of Henry Schein's (HSIC) planned spin-off of global Animal Health business. This business contributes nearly 30% to the company's top line.
Amedisys (AMED) Q1 Earnings, Revenues Beat on Overall Growth
by Zacks Equity Research
Robust growth in Medicare and non-Medicare revenues at Amedisys' (AMED) Home Health and Hospice divisions boost the company's Q1 results.
Phibro Animal (PAHC) Q3 Earnings Beat, Sales Improve Y/Y
by Zacks Equity Research
Phibro (PAHC) witnesses year-over-year improvement across all segments in Q3.
DaVita (DVA) Beats Q1 Earnings Estimates, Reiterates View
by Zacks Equity Research
Year-over-year growth in net dialysis and related lab patient service revenues boost DaVita's (DVA) bottom line in Q1.
PetMed (PETS) Q4 Earnings Top Estimates, Reorder Sales Solid
by Zacks Equity Research
PetMed (PETS) Q4 sales rise on increased reorders
Align Technology (ALGN) Beats on Earnings and Revenues in Q1
by Zacks Equity Research
Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q1.
Bruker (BRKR) Q1 Earnings & Revenues Beat, Margins Expand
by Zacks Equity Research
Bruker's (BRKR) Q1 benefits from improved European revenues, rising year over year in high-single digits.
ABIOMED (ABMD) Earnings Beat Estimates in Q4, View Impressive
by Zacks Equity Research
ABIOMED (ABMD) gains on surging Impella revenues, number of regulatory approvals.
Surmodics (SRDX) Beats on Q2 Earnings & Revenues, Raises View
by Zacks Equity Research
Surmodics' (SRDX) second-quarter fiscal 2018 results benefit from increase in royalty and license fee revenues.
DENTSPLY (XRAY) Beats Q1 Earnings Estimates, Lowers View
by Zacks Equity Research
Strong performance in Europe and Rest of World boosts DENTAPLY's (XRAY) performance in Q1. However, a lowered guidance indicates looming concerns.
IDEXX Laboratories (IDXX) Earnings, Revenues Rise in Q1
by Zacks Equity Research
IDEXX (IDXX) rides on strength in CAG business in Q1. A raised EPS guidance buoys optimism.